Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Patent Litigation
-
By Donald Zuhn — Valeant Pharmaceuticals International announced today (July 2, 2007) that it has settled its patent infringement suit with Kali Laboratories, Inc. (which was acquired by Par Pharmaceutical in June of 2004). Valeant’s patent infringement action involved Diastat®, which Valeant markets as the only FDA-approved at-home acute treatment for break-through epileptic…
-
By Jason Derry — Novogen Ltd. and Chattem, Inc. have reached a settlement, ending the legal action regarding isoflavone-containing health supplements. Novogen filed suit against Chattem, alleging that certain Chattem menopause products infringed two of Novogen’s U.S. patents – in particular, U.S. Patent Nos. 6,562,380 and 6,987,098. Novogen has previously enforced its patents…
-
Complete Ownership Is Required to Sue for Infringement By Baltazar Gomez — On June 18, 2007, the U.S. Supreme Court denied a petition from Israel Bio-Engineering Project (IBEP) for a writ of certiorari, and let stand an Federal Circuit ruling that IBEP cannot sue for infringement because it failed to show full patent…
-
By Donald Zuhn — Sanofi-Aventis and Bristol-Myers Squibb announced today (June 19, 2007) that the U.S. District Court for the Southern District of New York has issued a ruling in their favor in an infringement action against Apotex. Sanofi and BMS filed the action in March of 2002, contending that Apotex’ filing of…
-
By Donald Zuhn — On Monday, the U.S. Supreme Court denied a motion to expedite consideration of a petition for a writ of certiorari filed by Pfizer Inc. in Pfizer Inc. v. Apotex, Inc. (2007). The Chief Justice took no part in the consideration or decision of Pfizer’s motion. As previously reported by…
-
By Donald Zuhn — As recently reported on Patent Docs, the Senate Judiciary Committee conducted a hearing last week on patent reform. According to reports earlier today (June 12, 2007) at internetnews.com and InfoWorld, five Republican members of the Senate Judiciary Committee are now seeking to delay the Senate bill’s progress, saying the…
-
By Donald Zuhn — On Tuesday, Invitrogen Corporation and Clontech Laboratories, Inc. jointly announced that the two companies had reached a settlement in a patent litigation battle that had been begun more than 11 years earlier. Invitrogen had initiated the lawsuit when it filed a complaint against Clontech in December of 1996 in…
-
By Sherri Oslick — In a recent press release, ARIAD Pharmaceuticals, Inc. announced that it has filed suit against Amgen Inc., certain Amgen affiliates, and Wyeth for infringement of U.S. Patent No. 6,410,516 ("Nuclear Factors Associated with Transcriptional Regulation," issued June 25, 2002). The ‘516 patent is directed to certain aspects of the…
-
By Donald Zuhn — On Thursday, Allergan, Inc. announced that the U.S. Court of Appeals for the Federal Circuit has affirmed judgment in favor of Allergan and Roche Palo Alto, LLC in a patent infringement suit against Apotex, Inc., Apotex Corp., and Novex Pharma ("Apotex"). As a result of this decision, Apotex will…
-
By Donald Zuhn — As Patent Docs reported yesterday, Codon Devices, Inc., Duke University, and the Massachusetts Institute of Technology filed suit against Blue Heron Biotechnology on March 14th, asserting that Blue Heron’s manufacture and use of the GeneMaker® gene synthesis platform infringes plaintiffs’ U.S. Patent Nos. 5,459,039; 5,556,750; 5,679,522; 5,702,894; and 5,750,335…
Patent Docs 